Saudi Journal of Kidney Diseases and Transplantation (Jan 2016)

Renal impairment in multiple myeloma: A single center experience

  • Imen Gorsane,
  • S Barbouch,
  • M Mayara,
  • K Ben Abdelghani,
  • R Goucha,
  • F Ben Hamida,
  • H Hedri,
  • T Ben Abdallah

DOI
https://doi.org/10.4103/1319-2442.182380
Journal volume & issue
Vol. 27, no. 3
pp. 480 – 485

Abstract

Read online

To determine the features of the different forms of kidney diseases associated with multiple myeloma (MM), we retrospectively studied 144 patients with kidney injury and MM at our institute from 1974 to 2014. The mean age of the patients was 60.1 years and the male:female ratio was 1.25. Renal disease was concomitant with the discovery of MM in 92% of cases. The mean follow-up of our patients was 2.1 years. Initial renal insufficiency was found in 131 (91%) patients. Cast nephropathy of the distal tubule was found in 110 (26%) patients, renal amyloidosis in 16 (11.1%), and light chain deposition disease in five (3.47%). Twelve (8.3%) patients had chronic glomerular nephropathy. Twenty-six patients reached end-stage renal failure within 13.4 months. Renal survival was 30.45 months. Predictive factors for improvement of renal function undergoing chemotherapy included serum creatinine <250 µmol/L, proteinuria <1 g/24 h, and the non-use of renal replacement therapy. Multiple pathogenic mechanisms can contribute to kidney injury in myeloma patients. Novel myeloma agents have shown considerable promise in reversing renal failure in some patients and improving outcomes.